ArticleTranslational oncology2026
A renal cyst-clear cell renal cell carcinoma comorbidity analysis identifies a FOXM1-positive epithelial COL6A1-CD44 axis that remodels fibroblasts.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cystic conditions are heterogeneous. We used a broad renal cyst-associated disease-gene framework to identify molecular programs shared with clear cell renal cell carcinoma (ccRCC), without modeling a specific cystic disorder or direct cyst-to-cancer progression.
methodsWe identified 237 shared genes between renal cyst disease and ccRCC (TCGA-KIRC), performed functional enrichment, Mendelian randomization, and built a random survival forest (RSF) risk score benchmarked against published signatures and immunotherapy cohorts. Single-cell (Scissor, SCENIC, scTenifoldKnk virtual FOXM1 knockout) and spatial transcriptomics (RCTD, CellChat) were integrated with fibroblast subclustering and oncoPredict drug screening. Candidate FOXM1 inhibitors were prioritized by docking and 100-ns molecular dynamics, with isovitexin validated functionally.
resultsThe shared program was enriched for epithelial development and ECM remodeling. Two direction-specific Mendelian randomization analyses supported associations between genetic liability to kidney cancer and related renal cystic phenotypes. The RSF score showed robust prognostic discrimination across cohorts and separated immunotherapy outcomes. High-risk tumors were enriched for Tregs, B cells, and fibroblasts. FOXM1+ malignant epithelium represented the high-risk state, with elevated CNV burden and regulon activity; virtual FOXM1 knockout identified COL6A1 and CD44 among 129 significant non-target perturbation hits. Convergent single-cell and spatial analyses nominated a COL6A1-CD44 communication axis associated with fibroblast remodeling, with F5_SFRP2
conclusionsThese findings support a testable communication model involving FOXM1+ epithelium, COL6A1-CD44 and F5_SFRP2+ fibroblasts. The in vitro results also support further evaluation of isovitexin in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.